ELU42
Diabetic Foot Ulcers, Burns, Open Traumatic Soft Tissue Wounds
Pre-clinicalActive
Key Facts
Indication
Diabetic Foot Ulcers, Burns, Open Traumatic Soft Tissue Wounds
Phase
Pre-clinical
Status
Active
Company
About Eluciderm
Eluciderm is a private, pre-revenue biotech founded in 2016, developing a breakthrough topical small-molecule platform for regenerative wound healing and scar prevention. Its lead asset, ELU42, is poised to enter human trials for diabetic foot ulcers, burns, and open traumatic wounds, targeting massive, underserved markets with no FDA-approved scar prevention therapies. The company has secured key patents, won innovation awards, and is led by a founder with deep drug discovery expertise, positioning it to potentially transform point-of-care treatment in dermatology and wound care.
View full company profile